AI-Assisted Diabetes Education for Children With Type 1 Diabetes
The Effect of Artificial Intelligence-Assisted Education on Quality of Life, Diabetes Management, and Metabolic Control in Children With Type 1 Diabetes
This randomized controlled study evaluates the effects of an artificial intelligence-assisted diabetes education video on quality of life, diabetes self-management skills, and glycemic control in children with type 1 diabetes mellitus. Participants are assigned to an intervention group receiving a 12-minute educational video through a Meta Quest 2 virtual reality headset or a control group receiving routine diabetes education and care. Outcomes are assessed at baseline and at three months using validated questionnaires and routinely recorded HbA1c values.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This single-center, parallel-group randomized controlled study investigates the effects of artificial intelligence-assisted video-based diabetes education on health-related quality of life, diabetes self-management skills, and glycemic control among children and adolescents diagnosed with type 1 diabetes mellitus.
The study is conducted at the Pediatric Endocrinology Outpatient Clinic of Van Training and Research Hospital in Türkiye. A target sample of 60 participants was determined through an a priori power analysis, allowing for potential attrition. Eligible participants are allocated to an intervention group or a control group using a computer-generated random sequence.
Participants in the intervention group receive a 12-minute diabetes education video developed using artificial intelligence tools and delivered through a Meta Quest 2 virtual reality headset. The video content was prepared using established diabetes management guidelines. Artificial intelligence tools were used to develop the educational script, images, digital avatar, and voice narration. The virtual reality headset is used to support attention to the educational material. Disposable protective eye pads and headset cleaning procedures are used between participants to reduce the risk of cross-contamination.
Participants in the control group continue to receive routine diabetes education and clinical care. Outcomes are evaluated at baseline and three months after the intervention. Diabetes-specific quality of life is assessed using the PedsQL 3.0 Diabetes Module, and diabetes self-management skills are assessed using the Life Management Skills Scale for Children With Diabetes. Glycemic control is evaluated using HbA1c values obtained from routinely collected medical records. No additional blood samples or laboratory tests are requested for research purposes.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Nihat Güneş
- Telefonnummer: 05373083143
- E-mail: nihatgunes2314@gmail.com
Studiesteder
-
-
-
Van, Tyrkiet (Türkiye), 65100
- Rekruttering
- Van Training and Research Hospital
-
Kontakt:
- Nihat güneş
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Children and adolescents within the approved study age range.
- Diagnosis of type 1 diabetes mellitus at least six months before enrollment.
- Regular attendance at scheduled clinical follow-up visits.
- Ability to read and write.
- No communication barriers involving speech, hearing, or vision that would prevent participation.
Exclusion Criteria:
- Presence of a chronic disease other than type 1 diabetes mellitus.
- Unavailability of HbA1c measurements.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: AI-Assisted Diabetes Education
Participants receive a 12-minute diabetes education video developed with artificial intelligence tools and delivered through a Meta Quest 2 virtual reality headset. The educational material addresses essential aspects of type 1 diabetes management and is based on established diabetes guidelines. The headset is used to support participant attention during the educational session. |
Participants in the experimental group receive a 12-minute diabetes education video developed using artificial intelligence tools. The educational content is based on established diabetes management guidelines and covers essential aspects of type 1 diabetes management. The video was prepared using ChatGPT, Gemini, HeyGen, ElevenLabs, and CapCut and is delivered through a Meta Quest 2 virtual reality headset to support attention and engagement. Disposable protective eye pads are used, and the headset is cleaned between participants to reduce the risk of cross-contamination. |
|
Ingen indgriben: Routine Diabetes Education and Care
Participants in the control group continue to receive routine diabetes education, follow-up, and clinical care provided by the pediatric endocrinology outpatient clinic. They do not receive the artificial intelligence-assisted educational video. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diabetes-Specific Quality of Life
Tidsramme: Baseline and Month 3
|
Change in diabetes-specific quality of life from baseline to month 3, assessed using the Pediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module. The 28-item instrument is scored on a 0-100 scale, with higher scores indicating better quality of life. |
Baseline and Month 3
|
|
Diabetes Self-Management Skills
Tidsramme: Baseline and Month 3
|
Change in diabetes self-management skills from baseline to month 3, assessed using the Life Management Skills Scale for Children With Diabetes. The instrument contains 15 items covering diabetes management knowledge and coping skills. Higher scores indicate better life management skills. |
Baseline and Month 3
|
|
Glycemic Control (HbA1c)
Tidsramme: Baseline and Month 3
|
Change in glycated hemoglobin (HbA1c) percentage from baseline to month 3. HbA1c values are obtained from medical records following routine physician-ordered clinical assessments. No additional laboratory tests are performed specifically for this study. |
Baseline and Month 3
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- T1DM-AIEDU-2026-01
- GOKAEK/2026-02/68 (Anden identifikator: Van Training and Research Hospital Non-Interventional Clinical Research Ethics Committee)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data (IPD) will not be shared with other researchers due to privacy and confidentiality considerations, particularly because the study involves children and adolescents with type 1 diabetes mellitus. Data will be used only for the purposes approved by the ethics committee.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .